
James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

James F. Howard, MD, discusses the significance of the FDA expanding the label for efgartigimod in patients with generalized myasthenia gravis (gMG).

A retrospective analysis of Medicare claims was used to study emergency department (ED) dispositions, specifically evaluating inpatient admissions compared with home health referrals.